Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.

Abstract Multiple myeloma (MM) patients benefit from high dose chemotherapy, however relapse is inevitable and novel means of maintaining remission are required. Although oral thalidomide is an attractive agent for maintenance studies no careful dose finding studies have been performed in this setting. Given uncertainties about the long-term tolerability and the appropriate therapeutically active dose of thalidomide in this …